FDA Prioritizes Review of Elahere in Ovarian Cancer

The Food and Drug Administration has set priority review for Elahrere as use of treatment in patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Related Keywords

Michael Vasconcelles ,Drug Administration ,Immunogen Inc ,Biologics License Application ,Prescription Drug User Fee ,News ,Ovarian Cancer ,